Outcomes after Chemotherapy with WHO Category II Regimen in a Population with High Prevalence of Drug Resistant Tuberculosis

• Francine Matthys ,

  * E-mail: fmatthys@itg.be

  Affiliation Epidemiological and Disease Control Unit, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium

  ⨯
• Leen Rigouts,

  Affiliation Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium

  ⨯
• Vinciane Sizaire,

  Affiliation Médecins sans Frontières, Brussels, Belgium

  ⨯
• Natalia Vezhnina,

  Affiliation HIV/TB Penal System Projects in Central Asian Republics, AIDS Foundation East-West, Alma Ata, Kazakhstan

  ⨯
• Maryvonne Lecoq,

  Affiliation Médecins sans Frontières, Brussels, Belgium

  ⨯
• Vera Golubeva,

  Affiliation Laboratory of Mycobacteriology, Colony 33, Mariinsk, Kemorovo, Russia

  ⨯
• Françoise Portaels,

  Affiliation Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium

  ⨯
• Patrick Van der Stuyft,

  Affiliation Epidemiological and Disease Control Unit, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium

  ⨯
• Michael Kimerling

  Current address: The Bill and Melinda Gates Foundation, Seattle, Washington, United States of America

  Affiliation University of Alabama at Birmingham, Birmingham, Alabama, United States of America

  ⨯